KR101911362B1 - 타펜타돌을 함유하는 반고체 수성 약제학적 조성물 - Google Patents

타펜타돌을 함유하는 반고체 수성 약제학적 조성물 Download PDF

Info

Publication number
KR101911362B1
KR101911362B1 KR1020137026185A KR20137026185A KR101911362B1 KR 101911362 B1 KR101911362 B1 KR 101911362B1 KR 1020137026185 A KR1020137026185 A KR 1020137026185A KR 20137026185 A KR20137026185 A KR 20137026185A KR 101911362 B1 KR101911362 B1 KR 101911362B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
weight
semi
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137026185A
Other languages
English (en)
Korean (ko)
Other versions
KR20140013020A (ko
Inventor
울리히 라인홀트
마르크 쉴러
에바 불슈텐
사비너 카리너 카트린 잉겔브레흐트
로저르 카롤뤼스 아우귀스타 엠브러흐츠
울리히 파일
Original Assignee
그뤼넨탈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그뤼넨탈 게엠베하 filed Critical 그뤼넨탈 게엠베하
Publication of KR20140013020A publication Critical patent/KR20140013020A/ko
Application granted granted Critical
Publication of KR101911362B1 publication Critical patent/KR101911362B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020137026185A 2011-03-04 2012-03-02 타펜타돌을 함유하는 반고체 수성 약제학적 조성물 Expired - Fee Related KR101911362B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
US61/449,329 2011-03-04
EP11003603.5 2011-05-03
EP11003603 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029861A Division KR102039320B1 (ko) 2011-03-04 2012-03-02 타펜타돌을 함유하는 반고체 수성 약제학적 조성물

Publications (2)

Publication Number Publication Date
KR20140013020A KR20140013020A (ko) 2014-02-04
KR101911362B1 true KR101911362B1 (ko) 2018-10-25

Family

ID=44652117

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137026185A Expired - Fee Related KR101911362B1 (ko) 2011-03-04 2012-03-02 타펜타돌을 함유하는 반고체 수성 약제학적 조성물
KR1020187029861A Expired - Fee Related KR102039320B1 (ko) 2011-03-04 2012-03-02 타펜타돌을 함유하는 반고체 수성 약제학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187029861A Expired - Fee Related KR102039320B1 (ko) 2011-03-04 2012-03-02 타펜타돌을 함유하는 반고체 수성 약제학적 조성물

Country Status (24)

Country Link
US (3) US9446008B2 (enExample)
EP (3) EP2680834B1 (enExample)
JP (3) JP6027549B2 (enExample)
KR (2) KR101911362B1 (enExample)
CN (1) CN103501774A (enExample)
AU (2) AU2012224954C1 (enExample)
BR (1) BR112013022556A8 (enExample)
CA (1) CA2828637C (enExample)
CY (1) CY1119725T1 (enExample)
DK (1) DK2680834T3 (enExample)
EA (2) EA025194B1 (enExample)
ES (2) ES2910085T3 (enExample)
HR (1) HRP20171836T1 (enExample)
HU (1) HUE037491T2 (enExample)
IL (2) IL227826B (enExample)
LT (1) LT2680834T (enExample)
MX (2) MX344473B (enExample)
NO (1) NO2680834T3 (enExample)
PL (1) PL2680834T3 (enExample)
PT (2) PT2680834T (enExample)
RS (1) RS56692B1 (enExample)
SI (1) SI2680834T1 (enExample)
WO (1) WO2012119729A1 (enExample)
ZA (1) ZA201306480B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180116463A (ko) * 2011-03-04 2018-10-24 그뤼넨탈 게엠베하 타펜타돌을 함유하는 반고체 수성 약제학적 조성물

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX369121B (es) 2011-03-04 2019-10-30 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
US20160136112A1 (en) * 2013-08-02 2016-05-19 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
TW201642843A (zh) * 2015-03-27 2016-12-16 歌林達有限公司 他噴他多腸胃外給藥的穩定製劑
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
JP2021532112A (ja) * 2018-07-24 2021-11-25 ドクトア・アウグスト・ボルフ・ゲーエムベーハー・ウント・コンパニー・カー・ゲー−アルツナイミツテル 抗コリン性化合物の局所用エマルション
EP3846852A4 (en) 2018-09-07 2022-06-15 R.P. Scherer Technologies, LLC Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s)
CA3128882A1 (en) 2019-03-18 2020-09-24 Sunstar Americas, Inc. Oral care composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269326A1 (en) * 2007-03-12 2008-10-30 Gruenenthal Gmbh Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CA2479350A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
US20060111382A1 (en) 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
DK1612203T3 (da) 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
AR053304A1 (es) 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
MX2007013583A (es) 2005-04-28 2008-03-13 Theraquest Biosciences Llc Metodos y composiciones para tratar el dolor.
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
WO2007127158A2 (en) * 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
HRP20110271T1 (hr) 2006-04-28 2011-05-31 Grnenthal Gmbh Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek)
CN101431990B (zh) 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合
MX2009000911A (es) 2006-07-24 2009-02-04 Janssen Pharmaceutica Nv Preparacion de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina .
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP2219633A2 (en) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
ES2758831T3 (es) * 2008-10-30 2020-05-06 Gruenenthal Gmbh Nuevas y potentes formas de dosificación de tapentadol
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
JP5806287B2 (ja) * 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
US9446008B2 (en) * 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269326A1 (en) * 2007-03-12 2008-10-30 Gruenenthal Gmbh Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180116463A (ko) * 2011-03-04 2018-10-24 그뤼넨탈 게엠베하 타펜타돌을 함유하는 반고체 수성 약제학적 조성물
KR102039320B1 (ko) * 2011-03-04 2019-11-01 그뤼넨탈 게엠베하 타펜타돌을 함유하는 반고체 수성 약제학적 조성물

Also Published As

Publication number Publication date
CA2828637C (en) 2019-06-11
EA033171B1 (ru) 2019-09-30
HRP20171836T1 (hr) 2017-12-29
KR20180116463A (ko) 2018-10-24
KR20140013020A (ko) 2014-02-04
JP2014506900A (ja) 2014-03-20
EA201600442A1 (ru) 2017-02-28
IL227826B (en) 2018-04-30
AU2012224954A1 (en) 2013-09-19
PT3766489T (pt) 2022-04-07
JP6670283B2 (ja) 2020-03-18
AU2012224954C1 (en) 2017-04-06
AU2017200040A1 (en) 2017-02-02
EP2680834A1 (en) 2014-01-08
MX374468B (es) 2025-03-06
HUE037491T2 (hu) 2018-09-28
EA025194B1 (ru) 2016-11-30
EP3766489B1 (en) 2022-03-16
CA2828637A1 (en) 2012-09-13
SI2680834T1 (en) 2018-01-31
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
ZA201306480B (en) 2014-05-28
JP2017039756A (ja) 2017-02-23
JP2018065839A (ja) 2018-04-26
AU2012224954B2 (en) 2016-10-20
PL2680834T3 (pl) 2018-03-30
KR102039320B1 (ko) 2019-11-01
PT2680834T (pt) 2018-01-25
BR112013022556A2 (pt) 2016-12-06
ES2654407T3 (es) 2018-02-13
BR112013022556A8 (pt) 2018-01-16
DK2680834T3 (en) 2017-12-04
EA201300988A1 (ru) 2014-06-30
EP2680834B1 (en) 2017-10-18
ES2910085T3 (es) 2022-05-11
US9446008B2 (en) 2016-09-20
CN103501774A (zh) 2014-01-08
WO2012119729A1 (en) 2012-09-13
US20120225950A1 (en) 2012-09-06
JP6259042B2 (ja) 2018-01-10
EP3290029A1 (en) 2018-03-07
MX344473B (es) 2016-12-16
RS56692B1 (sr) 2018-03-30
IL258357A (en) 2018-05-31
LT2680834T (lt) 2018-01-10
JP6027549B2 (ja) 2016-11-16
NO2680834T3 (enExample) 2018-03-17
US20180133174A1 (en) 2018-05-17
CY1119725T1 (el) 2018-06-27
EP3766489A1 (en) 2021-01-20
EP3290029B1 (en) 2020-09-02
IL227826A0 (en) 2013-09-30
AU2017200040B2 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
KR102039320B1 (ko) 타펜타돌을 함유하는 반고체 수성 약제학적 조성물
KR101946790B1 (ko) 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
DK2600851T3 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN
KR20200119351A (ko) 수계 캡사이시노이드 제형 및 제조 방법 및 용도
US20130052241A1 (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JP2025085814A (ja) 医薬組成物
ES2822023T3 (es) Composición farmacéutica acuosa semisólida que contiene tapentadol
HK1194966B (en) Semisolid aqueous pharmaceutical composition containing tapentadol
HK1194966A (en) Semisolid aqueous pharmaceutical composition containing tapentadol
TW201832765A (zh) 膀胱內投藥用於治療膀胱痛之組合物
WO2018153947A1 (en) Tapentadol as local anesthetic

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211019

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211019